Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis
- PMID: 21040935
- DOI: 10.1016/j.metabol.2010.09.003
Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis
Abstract
Hypoadiponectinemia might represent a risk factor for nonalcoholic fatty liver disease (NAFLD). We performed a systematic review and meta-analysis to evaluate the serum total adiponectin levels in patients with simple nonalcoholic fatty liver (NAFL), those with nonalcoholic steatohepatitis (NASH), and controls. Data were extracted from PubMed, EMBASE, and Cochrane Central Register of Controlled Trials electronic databases (up to December 2009). The main outcome was the weighted mean differences (WMDs) in adiponectin between comparison groups. Twenty-eight studies were included in the systematic review. A meta-analysis of 27 studies that reported data on 2243 subjects (698 controls and 1545 patients with NAFLD) was performed. Controls had higher serum adiponectin compared with NAFL patients (12 studies, random-effects WMD [95% confidence interval {CI}] = 3.00 [1.57-4.43], I² = 80.4%) or NASH patients (19 studies, random-effects WMD [95% CI] = 4.75 [3.71-5.78], I² = 84.1%). The NASH patients demonstrated lower adiponectin compared with NAFL patients (19 studies, random-effects WMD [95% CI] = 1.81 [1.09-2.53], I² = 71.7%). By performing a meta-regression analysis, body mass index, age, sex, and type 2 diabetes mellitus failed to account for heterogeneity. However, the performance of liver biopsy on controls had significant effect on the outcome and accounted for 76.7%, 85.5%, and 22.8% of the between-study variance for comparisons between controls vs NAFLD, NAFL, and NASH patients, respectively. Based on liver histology, serum adiponectin levels are similar in NAFL patients and controls, but hypoadiponectinemia may play an important pathophysiological role in the progression from NAFL to NASH.
Copyright © 2011 Elsevier Inc. All rights reserved.
Similar articles
-
Irisin in patients with nonalcoholic fatty liver disease.Metabolism. 2014 Feb;63(2):207-17. doi: 10.1016/j.metabol.2013.09.013. Epub 2013 Oct 18. Metabolism. 2014. PMID: 24140091
-
Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: Introduction of CHA index.Ann Hepatol. 2013 Sep-Oct;12(5):749-57. Ann Hepatol. 2013. PMID: 24067262
-
Association of serum ferritin with non-alcoholic fatty liver disease: a meta-analysis.Lipids Health Dis. 2017 Dec 2;16(1):228. doi: 10.1186/s12944-017-0613-4. Lipids Health Dis. 2017. PMID: 29197393 Free PMC article.
-
Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies.Clin Gastroenterol Hepatol. 2015 Apr;13(4):643-54.e1-9; quiz e39-40. doi: 10.1016/j.cgh.2014.04.014. Epub 2014 Apr 24. Clin Gastroenterol Hepatol. 2015. PMID: 24768810 Free PMC article. Review.
-
Circulating Ferritin in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis.J Clin Exp Hepatol. 2024 May-Jun;14(3):101353. doi: 10.1016/j.jceh.2024.101353. Epub 2024 Feb 2. J Clin Exp Hepatol. 2024. PMID: 38435724 Review.
Cited by
-
Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment.Curr Pharm Des. 2013;19(29):5219-38. doi: 10.2174/13816128113199990381. Curr Pharm Des. 2013. PMID: 23394097 Free PMC article.
-
Should visceral fat, strictly linked to hepatic steatosis, be depleted to improve survival?Hepatol Int. 2013 Jun;7(2):413-28. doi: 10.1007/s12072-012-9406-z. Epub 2012 Oct 26. Hepatol Int. 2013. PMID: 26201775
-
Non-alcoholic fatty liver disease and psoriasis: So far, so near.World J Hepatol. 2015 Mar 27;7(3):315-26. doi: 10.4254/wjh.v7.i3.315. World J Hepatol. 2015. PMID: 25848461 Free PMC article. Review.
-
Biomarkers in nonalcoholic fatty liver disease.Can J Gastroenterol Hepatol. 2014 Dec;28(11):607-18. doi: 10.1155/2014/757929. Can J Gastroenterol Hepatol. 2014. PMID: 25575111 Free PMC article. Review.
-
The Correlation Between Serum Adipokines and Liver Cell Damage in Non-Alcoholic Fatty Liver Disease.Hepat Mon. 2016 Apr 20;16(5):e37412. doi: 10.5812/hepatmon.37412. eCollection 2016 May. Hepat Mon. 2016. PMID: 27313636 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources